The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
40 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $15,078,023 in first-year total cost, median $428,026.
Most frequent study sections
- Special Emphasis Panel[ZAI1 AMC-W (M1)]3
- Special Emphasis Panel[ZAI1 CB-W (S2)]3
- Special Emphasis Panel[ZAI1 IS-W (S1)]3
- Special Emphasis Panel[ZAI1 IS-W (S2)]3
- Special Emphasis Panel[ZAI1 JHM-X (S3)]3
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN DIEGO3
- COLORADO STATE UNIVERSITY2
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE2
- TULANE UNIVERSITY OF LOUISIANA2
- UNIVERSITY OF UTAH2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Elucidating Airborne SARS-CoV-2 Infectivity at Single Aerosol Resolution1R21AI161501-01 | DEVOE, DON LMILTON, DONALD KIRBY | UNIV OF MARYLAND, COLLEGE PARK, MD | $414,425 | ZAI1 |
| 2021 | Identifying and inhibiting the SARS-CoV-2 packaging mechanism1R21AI159666-01 | DOUDNA, JENNIFER A | J. DAVID GLADSTONE INSTITUTES, CA | $519,750 | ZAI1 |
| 2021 | Defining therapeutic drug targets for SARS-CoV-2-specific and pan-coronavirus inhibition1R21AI161212-01 | RICE, CHARLES M | ROCKEFELLER UNIVERSITY, NY | $483,500 | ZAI1 |
| 2021 | Exploring the Coronavirus Exoribonuclease as an Antiviral Target1R21AI161230-01 | WELLER, SANDRA KWRIGHT, DENNIS L. | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, CT | $463,700 | ZAI1 |
| 2021 | Targeting Coronavirus through Nucleocapsid Phosphorylation1R21AI161678-01 | KLEIN, PETER S | UNIVERSITY OF PENNSYLVANIA, PA | $446,875 | ZAI1 |
| 2021 | Identification of Host Directed Drug Targets for SARS-CoV-2 Using Transposon Mutagenesis1R21AI161275-01 | BRUCHEZ, ANNA | CASE WESTERN RESERVE UNIVERSITY, OH | $442,750 | ZAI1 |
| 2021 | Accelerated discovery of cell-active SARS-CoV-2 polymerase inhibitors via molecular dynamic guided screening and optimization1R21AI161232-01 | GOLDEN, JENNIFER E. | UNIVERSITY OF WISCONSIN-MADISON, WI | $442,542 | ZAI1 |
| 2021 | GS-441524 is Pharmacodynamically Equivalent to Remdesivir and Pharmacokinetically Superior Drug for the Treatment of COVID-191R21AI159246-01 | LI, CHUN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $442,002 | ZAI1 |
| 2021 | Elucidating the transcriptional mechanisms that control the expression of the SARS-CoV-2 receptor ACE21R21AI158240-01 | XU, JIAN | UT SOUTHWESTERN MEDICAL CENTER, TX | $441,479 | ZAI1 |
| 2021 | Novel small-molecule inhibitors of SARS-CoV-2 protease1R21AI159323-01 | SONG, YONGCHENG | BAYLOR COLLEGE OF MEDICINE, TX | $440,000 | ZAI1 |
| 2021 | In vivo tracking of inhaled ACE2 targeting theranostic nanodrugs delivery to the lungs using magnetic particle imaging1R21AI159928-01 | WANG, PING | MICHIGAN STATE UNIVERSITY, MI | $430,375 | ZAI1 |
| 2021 | RNA-dependent RNA Polymerase Assays for Biochemical Characterization and Antiviral Drug Discovery1R21AI157903-01 | VAN LANEN, STEVEN GARY | UNIVERSITY OF KENTUCKY, KY | $417,474 | ZAI1 |
| 2021 | Develop Potent Methyltransferase Inhibitors to Target Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)1R21AI158176-01 | ZHENG, Y. GEORGE | UNIVERSITY OF GEORGIA, GA | $415,250 | ZAI1 |
| 2021 | Develop novel inhaled neutralizing RNA therapeutics against COVID-191R21AI161075-01 | ROSSI, JOHN JOSEPH | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $396,000 | ZAI1 |
| 2021 | Targeting a Human Acyltransferase for Broad-Spectrum Antivirals1R21AI160508-01 | LOWERY, ROBERT G | BELLBROOK LABS, LLC, WI | $390,500 | ZAI1 |
| 2021 | Host inflammatory response to SARS-CoV-21R21AI158788-01 | GALE, MICHAEL | UNIVERSITY OF WASHINGTON, WA | $264,750 | ZAI1 |
| 2021 | Integrated Analysis of SARS-CoV-2 Vaccine Responses During Aging1R21AI158175-01 | SAGE, PETER THE | BRIGHAM AND WOMEN'S HOSPITAL, MA | $255,860 | ZAI1 |
| 2021 | T cell modulation of COVID-19 disease1R21AI161567-01 | MANESS, NICHOLAS JAMES | TULANE UNIVERSITY OF LOUISIANA, LA | $255,000 | ZAI1 |
| 2021 | Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and Disease1R21AI160334-01 | WOODFOLK, JUDITH A | UNIVERSITY OF VIRGINIA, VA | $242,250 | ZAI1 |
| 2021 | MHC class II immunopeptidomics analysis of the SARS-CoV-2 proteome1R21AI158278-01 | LOCHHEAD, ROBERT | MEDICAL COLLEGE OF WISCONSIN, WI | $234,000 | ZAI1 |
| 2021 | Role of Salivary Gland Localized SARS-CoV-2 Infection in Oral Tolerance & Immunization Efficacy1R21AI161600-01 | WELLER, MELODIE LYNN | UNIVERSITY OF UTAH, UT | $228,750 | ZAI1 |
| 2021 | VPS34 inhibitors as SARS-CoV-2 antivirals1R21AI161104-01 | BASLER, CHRISTOPHER F | GEORGIA STATE UNIVERSITY, GA | $13,111 | ZAI1 |
| 2020 | ADE-minimized COVID-19 vaccine via epitope focusing and anti-inflammatory innate immunity1R21AI157604-01 | CARDOZO, TIMOTHY J | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $466,125 | ZAI1 |
| 2020 | Accurate prediction of neutralization capacity from deep mining of SARS-CoV-2 serology1R21AI158997-01 | KOIDE, SHOHEI | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $466,125 | ZAI1 |
| 2020 | SARS-CoV-2 and Influenza Infection in the Syrian Hamster1R21AI158179-01 | ZEISS, CAROLINE J | YALE UNIVERSITY, CT | $450,500 | ZAI1 |
| 2020 | CRISPR screens for SARS-CoV-2 Host Factors1R21AI157835-01 | DOENCH, JOHN GERARD | BROAD INSTITUTE, INC., MA | $440,000 | ZAI1 |
| 2020 | Generating Novel Humanized Mouse Models for in vivo COVID19 Mechanism Studies and Therapeutics Tests1R21AI157942-01 | VERHEYDEN, JAMIE M | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $434,000 | ZAI1 |
| 2020 | Imaging SARS-CoV-2 proteases for spatio-temporal insight into Covid-191R21AI157957-01 | JOKERST, JESSE VINCENT | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $433,927 | ZAI1 |
| 2020 | Designing neutralization antibodies against Sars-Cov-21R21AI158114-01 | WANG, WEI | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $433,750 | ZAI1 |
| 2020 | Targeting SARS-Related Coronaviruses with a D-peptide Entry Inhibitor1R21AI158568-01 | KAY, MICHAEL S | UNIVERSITY OF UTAH, UT | $429,481 | ZAI1 |
| 2020 | Toward a protective Covid-19 vaccine utilizing an established vector platform1R21AI158044-01 | SCHNELL, MATTHIAS JOHANNES | THOMAS JEFFERSON UNIVERSITY, PA | $429,000 | ZAI1 |
| 2020 | Inflammatory cytokines and pyroptosis in Coronavirus infection1R21AI158064-01 | RE, FABIO C | ROSALIND FRANKLIN UNIV OF MEDICINE & SCI, IL | $429,000 | ZAI1 |
| 2020 | Development of Broad-Spectrum Antiviral Therapeutics by Destabilizing the Main Protease of Coronaviruses1R21AI158210-01 | TANG, WEIPING | UNIVERSITY OF WISCONSIN-MADISON, WI | $427,052 | ZAI1 |
| 2020 | SARS-CoV-2 and Autophagy1R21AI158134-01 | JACKSON, WILLIAM T | UNIVERSITY OF MARYLAND BALTIMORE, MD | $424,875 | ZAI1 |
| 2020 | Immunomodulatory effects of coronavirus membrane proteins E, M, and S.1R21AI158229-01 | KALAMVOKI, MARIASTEPHENS, EDWARD BRICE | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $420,750 | ZAI1 |
| 2020 | Recombinant BCG-based SARS-CoV-2 vaccine1R21AI158056-01 | JACKSON, MARY | COLORADO STATE UNIVERSITY, CO | $411,968 | ZAI1 |
| 2020 | Mechanisms and functional implications of SARS-CoV-2 mRNA capping and modification.1R21AI158335-01 | GEISS, BRIANWILUSZ, JEFFREY | COLORADO STATE UNIVERSITY, CO | $407,060 | ZAI1 |
| 2020 | EVOLVING VIRUS-SPECIFIC sACE2 MIMICS FOR COMPETITIVE INHIBITION OF SARS-CoV-21R21AI158169-01 | ESVELT, KEVIN | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $399,346 | ZAI1 |
| 2020 | Persistence of SARS-CoV-2 in Wastewater1R21AI157434-01 | SHERCHAN, SAMENDRA P | TULANE UNIVERSITY OF LOUISIANA, LA | $89,989 | ZAI1 |
| 2020 | Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors1R21AI157606-01 | COUGHLAN, LYNDA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $4,732 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.